Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tvardi TherapeuticsLTS:0HTC 8 3-Year EBITDA Growth Rate is 24.50% as of Jun. 2026, which is at its 10-year median of 24.50. GuruFocus rates LTS:0HTC with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 1,125 Biotechnology companies, Tvardi Therapeutics ranks better than 61.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 24.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tvardi Therapeutics was 24.50% per year. The lowest was 24.50% per year. And the median was 24.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tvardi Therapeutics 3-Year EBITDA Growth Rate Related Terms
LTS:0HTC vs PVCT, CLRB, DYAI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 24.50% mean?
Tvardi Therapeutics (LTS:0HTC) has a 3-Year EBITDA Growth Rate of 24.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tvardi Therapeutics and its competitors. This is near median its historical median of 24.50. Over the past decade, Tvardi Therapeutics' 3-Year EBITDA Growth Rate has ranged from 24.50 to 24.50. According to the industry distribution chart, Tvardi Therapeutics ranks #438 out of 1125 companies in the Biotechnology industry, placing it in the top 38.9%.
Is Tvardi Therapeutics' 3-Year EBITDA Growth Rate too high?
Tvardi Therapeutics' current 3-Year EBITDA Growth Rate of 24.50% is near median its 10-year median of 24.50. Over the past 10 years, this metric has ranged from a low of 24.50 to a high of 24.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Tvardi Therapeutics' value of 24.50% is 66.7% above this industry median. Based on the distribution chart, Tvardi Therapeutics ranks #438 out of 1125 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' 3-Year EBITDA Growth Rate compare to PVCT and CLRB?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #438 out of 1125 companies for 3-Year EBITDA Growth Rate. This puts Tvardi Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. Tvardi Therapeutics' value of 24.50% is 66.7% above this benchmark. Historically, Tvardi Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 24.50 to 24.50 over the past decade. While the company's 10-year median is 24.50 vs. the industry median of 14.70, Tvardi Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,125 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tvardi Therapeutics's current 3-Year EBITDA Growth Rate of 24.50% is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current 3-Year EBITDA Growth Rate is 24.50%, which is near median its own 10-year median of 24.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current 3-Year EBITDA Growth Rate of 24.50%. The current 3-Year EBITDA Growth Rate is 24.50%, which is near median its 10-year median of 24.50 and 66.7% above the Biotechnology industry median of 14.70. Tvardi Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current 3-Year EBITDA Growth Rate is 24.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
8GF Score
Get the complete analysis for LTS:0HTC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 
